Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)

Introduction Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics. Methods Centres popul...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	HIV medicine 2024-10, Vol.25 (10), p.1125-1134
Hauptverfasser:	Ring, Kyle, Smuk, Melanie, Shongwe, Moses, Okonta, Leroy, Mackie, Nicola E., Ayres, Sara, Barber, Tristan J., Akodu, Jane, Ferro, Filippo, Chilton, Daniella, Hurn, Eliot, Halai, Bhavna, Barchi, Will, Ali, Asim, Darko, Sandra, White, Gemma, Clarke, Emily, Clark, Fiona, Ali, Bazga, Arumainayagam, Joseph, Quinn, Gaynor, Boffito, Marta, Byrne, Ruth, Naous, Nadia, Leung, Suki, Umaipalan, Athavan, Thornton, Brian, Bayliss, David, McLoughlin, Catherine, Foster, Jonathan, Waters, Laura, Orkin, Chloe
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Cabotegravir capacity Clinics discontinuation effectiveness HIV Information processing long‐acting injectable real‐world evidence Rilpivirine Viremia Virologic suppression
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!